Transaction in Own Shares - Replacement

Summary by AI BETAClose X

Allianz Technology Trust PLC announced an amendment to a prior announcement regarding a transaction in its own shares; the total voting rights figure was revised to 368,856,263. The company purchased 200,000 ordinary shares to be held in treasury at 511.00p per share. Following this transaction, the company's issued ordinary share capital is 428,756,680, with 59,900,417 ordinary shares held in treasury, which do not carry voting rights. The amended total voting rights figure of 368,856,263 should be used by shareholders to determine if they need to notify their interest in the company under FCA rules.

Disclaimer*

Allianz Technology Trust PLC
06 October 2025
 

ALLIANZ TECHNOLOGY TRUST PLC

LEI: 549300OMDPMJU23SSH75

The following amendment has been made to the 'Transaction in Own Shares' announcement released on 03/10/2025 at 17:18 under RNS No 0782C.

The total voting rights figure has been amended from 368,856,680 to 368,856,263.

All other details remain unchanged.

The full amended text is shown below.

 

3 October 2025

Allianz Technology Trust PLC announces that it today purchased, to be held in treasury, 200,000 ordinary shares at 511.00p per ordinary share.

Following the transaction:

·    The Company's issued ordinary share capital is 428,756,680.

·    59,900,417 ordinary shares are held in Treasury, which attract no voting rights.

·    The total number of voting rights in the Company is now 368,856,263

The above total voting rights figure (368,856,263) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

Nira Mistry

Company Secretary

Tel: 075 5422 4339

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings